Amyloid Imaging–Based Food and Drug Administration Approval of Lecanemab to Treat Alzheimer Disease—What Lasts Long Finally Becomes Good?
Journal of Nuclear Medicine · 2023
DOI: 10.2967/jnumed.123.265667 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Henryk Barthel. Beteiligte Einrichtung: Leipzig University Medical Center, Leipzig, Germany henryk.barthel@medizin.uni-leipzig.de. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
![Figure][1] Henryk Barthel Alzheimer disease (AD) is a devastating neurologic condition of high socioeconomic relevance. Although today this disease can be accurately diagnosed during a lifetime, especially with the help of molecular imaging approaches such as amyloid PET, tau PET or 18F-
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Leipzig University Medical Center, Leipzig, Germany henryk.barthel@medizin.uni-leipzig.de.
Zitieren
APA
Barthel, H. (2023). Amyloid Imaging–Based Food and Drug Administration Approval of Lecanemab to Treat Alzheimer Disease—What Lasts Long Finally Becomes Good?. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.265667
Vancouver
Barthel H. Amyloid Imaging–Based Food and Drug Administration Approval of Lecanemab to Treat Alzheimer Disease—What Lasts Long Finally Becomes Good?. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.265667
BibTeX
@article{Barthel2023,
author = {Barthel, Henryk},
title = {Amyloid Imaging–Based Food and Drug Administration Approval of Lecanemab to Treat Alzheimer Disease—What Lasts Long Finally Becomes Good?},
journal = {Journal of Nuclear Medicine},
year = {2023},
doi = {10.2967/jnumed.123.265667}
}
EUVIMED